The launch of the final recommendations of SISAQOL-IMI – EORTC
EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn by SISAQOL-IMI, adding:
“We are excited to announce the launch of the final recommendations of SISAQOL-IMI, a global initiative co-led by EORTC and Boehringer Ingelheim under the Innovative Medicines Initiative (IMI).
This multidisciplinary consortium, bringing together 41 international stakeholders, has developed consensus-based guidelines to standardise the analysis of patient-reported outcomes (PROs) and health-related quality of life (HRQOL) data in cancer clinical trials.
On 4 February 2025, which was also World Cancer Day, SISAQOL-IMI hosted a public launch event in Ghent, Belgium, presenting these recommendations and discussing their impact on future research, clinical trials, and patient care.
Next steps? Training, dissemination, and long-term accessibility via an interactive web tool to ensure these guidelines drive meaningful change in oncology research.
Quoting SISAQOL-IMI’s post:
“Yesterday, SISAQOL-IMI officially launched its final recommendations for standardising patient-reported outcomes in cancer clinical trials! A huge step toward better, more reliable data for patient-centered care.
More posts featuring EORTC.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023